Partial adenosine A1 receptor agonists for cardiovascular therapies
- 12 November 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Purinergic Signalling
- Vol. 8 (S1), 91-99
- https://doi.org/10.1007/s11302-011-9274-3
Abstract
Adenosine, a purine nucleoside, is present in all cells in tightly regulated concentrations. It has many different physiological effects in the whole body and in the heart. Adenosine activates four G protein-coupled receptors A1, A2a, A2b, and A3. Activation of myocardial A1 receptors has been shown to inhibit a variety of myocardial pathologies associated with ischemia and reperfusion injury, including stunning, arrhythmogenesis, coronary and ventricular dysfunction, acute myocardial infarction, apoptosis, and chronic heart failure, implying several options for new cardiovascular therapies for diseases, like angina pectoris, control of cardiac rhythm, ischemic injury during an acute coronary syndrome, or heart failure. However, the main issue of using full A1 receptor agonists in such indications is the broad physiologic spectrum of cardiac and extracardiac effects. Desired A1 receptor-mediated protective and regenerative cardiovascular effects might be counter-regulated by unintended side effects when considering full A1 receptor agonists. These effects can be overcome by partial A1 agonists. Partial A1 agonists can be used to trigger only some of the physiological responses of receptor activation depending on endogenous adenosine levels and on receptor reserve in different tissues. CV-Therapeutics reported the identification of a partial A1 receptor agonist CVT-3619, and recently, another partial A1 receptor agonist VCP28 was published. Both compounds are adenosine derivatives. Adenosine-like A1 receptor agonists often have the drawback of a short half-life and low bioavailability, making them not suitable for chronic oral therapy. We identified the first non-adenosine-like partial A1 receptor agonist(s) with pharmacokinetics optimal for oral once daily treatment and characterized the qualities of the partial character of the A1 receptor agonist(s) in preclinical and clinical studies.Keywords
This publication has 44 references indexed in Scilit:
- A Novel Highly Selective Adenosine A1 Receptor Agonist VCP28 Reduces Ischemia Injury in a Cardiac Cell Line and Ischemia–Reperfusion Injury in Isolated Rat Hearts at Concentrations That Do Not Affect Heart RateJournal of Cardiovascular Pharmacology, 2010
- Adenosine Receptors and Reperfusion Injury of the HeartHandbook of Experimental Pharmacology, 2009
- Adenosine Receptors and the Heart: Role in Regulation of Coronary Blood Flow and Cardiac ElectrophysiologyHandbook of Experimental Pharmacology, 2009
- Antilipolytic Activity of a Novel Partial A1Adenosine Receptor Agonist Devoid of Cardiovascular Effects: Comparison with Nicotinic AcidJournal of Pharmacology and Experimental Therapeutics, 2007
- Survival kinases in ischemic preconditioning and postconditioningCardiovascular Research, 2006
- Genetic Deletion of the A 1 Adenosine Receptor Limits Myocardial Ischemic ToleranceCirculation Research, 2005
- Adenosine in Tissue Protection and Tissue Regeneration: TABLE 1Molecular Pharmacology, 2005
- Activation of Adenosine A 1 Receptor Attenuates Cardiac Hypertrophy and Prevents Heart Failure in Murine Left Ventricular Pressure-Overload ModelCirculation Research, 2003
- Prolonging the Delayed Phase of Myocardial Protection: Repetitive Adenosine A1Receptor Activation Maintains Rabbit Myocardium in a Preconditioned State 11Dr. Dana is supported by a Junior Research Fellowship, and Dr. Baxter by an Intermediate Fellowship, from the British Heart Foundation, London. Continuing support (Drs. Dana and Baxter) is provided by the Hatter Foundation, London.Journal of the American College of Cardiology, 1998
- Species comparison of adenosine and β-adrenoceptors in mammalian atrial and ventricular myocardiumEuropean Journal of Pharmacology: Molecular Pharmacology, 1993